Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Western Sierra Resource Corporation (WSRC)
Edmond, OK, US
Western Sierra Resource Corporation (WSRC) operates primarily as a gold and silver extraction company, with operations located across Arizona, Nevada, California, and Mexico. Its assets include six precious metal reserves in Arizona and one in Nevada. Beyond its core mining activities, WSRC also oversees a variety of mineral resource ventures in the Southwestern United States, encompassing properties for precious metals, helium, and natural gas. Additionally, the company possesses water and infrastructure assets in Northwest Colorado, which are designated for facilitating industrial hemp irrigation, processing, and the production of hemp-based construction materials. These materials are intended for building affordable housing directly at a resort location. Founded in 1907, the company, originally named Western Sierra Mining Corp., adopted its current identity as Western Sierra Resource Corporation in September 2018. WSRC maintains its corporate headquarters in Edmond, Oklahoma.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | +0.00% | +0.00% | -99.86% | -99.67% | -97.50% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-70.3% Q1'23: +1,233.0% (vs Q1'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-70.8% Q1'23: +375.0% (vs Q1'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+42.0% Q1'23: -60.9% (vs Q1'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+65.6% ★ Q1'23: +24.7% (vs Q1'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.3% Q1'23: +3.4% (vs Q1'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-3.1% ★ Q1'23: +8.0% (vs Q1'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×41.39× Q1'23: 4.14× (vs Q1'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dennis Atkins | Chief Financial Officer & Director | 90.0K | male |
| Roger Johnson | President, Chief Executive Officer & Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WSRC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
